Thermo Fisher Secures FDA Clearance for First-of-Its-Kind Automated System to Transform Multiple Myeloma Diagnosis

First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved laboratory workflow to suppor...

November 13, 2025 | Thursday | Regulatory
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis

 LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 cl...

November 11, 2025 | Tuesday | News
Nurami Medical Advances Artifix® Toward First-in-Human Trials With Successful Phase 1 Completion

Nurami Medical, a company developing next-generation regenerative solutions for soft tissue repair, has announced successful completion of Phase 1 of...

November 11, 2025 | Tuesday | News
Vascarta and CUNY Report Preclinical Breakthrough Demonstrating STO-1 Selectively Eliminates Glioblastoma Cells

Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...

November 11, 2025 | Tuesday | News
SanegeneBio and Eli Lilly Announce Global Collaboration on RNAi Therapies for Metabolic Diseases

  SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collab...

November 10, 2025 | Monday | News
Merck Presents Phase 3 Data Showing Enlicitide Achieved Up to 60% LDL-C Reduction With Placebo-Like Safety

Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety pr...

November 10, 2025 | Monday | Reports
Dupixent Delivers First Positive Phase 3 Results in Allergic Fungal Rhinosinusitis

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal cong...

November 10, 2025 | Monday | News
Facet Life Sciences and XCancer Form Strategic Partnership to Accelerate Development of Theranostic Radiopharmaceuticals

Facet Life Sciences, a leader in regulatory strategy and drug development services, announced a strategic partnership with XCancer®, a global leader ...

November 07, 2025 | Friday | News
Alvotech and Advanz Pharma Receive UK Marketing Authorisations for Gobivaz®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Adva...

November 07, 2025 | Friday | News
Harrison.ai Launches Zero-Markup Open Platform to Transform Deployment of Medical Imaging AI

Leading AI Vendors AZmed, CoLumbo, Lucida Medical, Nicolab, Radiobotics, Therapixel, and Us2.ai Join as Launch Partners alongside Harrison.ai native ap...

November 06, 2025 | Thursday | News
Clearmind Medicine Files Patent in South Korea for MEAI in Depression Treatment

Patent expands MEAI’s global intellectual property protection as Clearmind advances clinical development and commercialization plans Clearmind Med...

November 06, 2025 | Thursday | News
Jupiter Neurosciences Receives FDA IND Clearance to Initiate Phase 2a Trial of JOTROL™ in Parkinson’s Disease

Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic pla...

November 06, 2025 | Thursday | News
Normunity Doses First Patient in Phase 1 Trial of NRM-823, a First-in-Class T Cell Engager

Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastat...

November 06, 2025 | Thursday | News
INOVIO Completes BLA Submission for INO-3107, a DNA Immunotherapy for Recurrent Respiratory Papillomatosis

Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously rece...

November 04, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close